Barclays analyst Carter Gould maintains $AbbVie (ABBV.US)$ with a buy rating, and maintains the target price at $212.
According to TipRanks data, the analyst has a success rate of 48.6% and a total average return of 8.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:
AbbVie has recorded another remarkable quarter, shifting the attention towards emraclidine and the year 2025.
Following AbbVie's report of robust Q3 results and an increase in revenue guidance for 2024, there's an acknowledgment of the company's strong prospects heading towards the year-end. This positive sentiment is supported by a more optimistic 2025 earnings per share forecast. Nevertheless, the assessment of the company's long-term growth potential is measured against its present market valuation.
Following AbbVie's third-quarter report, which surpassed expectations and projected higher future earnings, confidence in the company's growth outlook has been bolstered. The revision of estimates is primarily due to increased projections for Rinvoq and Skyrizi, although this is somewhat balanced by tempered forecasts for aesthetics and Humira sales.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
